Versant Capital Management, Inc Sage Therapeutics, Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 505 shares of SAGE stock, worth $4,620. This represents 0.0% of its overall portfolio holdings.
Number of Shares
505
Previous 1,485
65.99%
Holding current value
$4,620
Previous $12,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding SAGE
# of Institutions
218Shares Held
49.9MCall Options Held
220KPut Options Held
312K-
Black Rock Inc. New York, NY5.22MShares$47.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$46.5 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$41 Million4.6% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$25 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$19.1 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $544M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...